The idea that an AI system can autonomously clear a chest X-ray -- with no radiologist in the loop -- has been one of radiology's most debated propositions. Now it is moving from debate to deployment. Sectra, the Swedish medical imaging IT company listed on the Stockholm Stock Exchange (STO: SECT B), has agreed to acquire Oxipit, a Lithuanian startup that holds the first CE Class IIB certification for autonomous AI in chest X-ray analysis.

The acquisition, announced on March 5, is not just a technology deal. It is a regulatory milestone. Oxipit's ChestLink system can autonomously identify and report normal chest X-rays without requiring a radiologist to review them first. That capability -- fully autonomous diagnostic reporting -- is something that most AI companies in radiology have not been able to achieve from a regulatory standpoint, and it is the reason Sectra is writing the check.

"The combination of Sectra's medical imaging IT solutions and Oxipit's autonomous AI capabilities will provide unique value for healthcare providers around the world," said Torbjorn Kronander, Sectra's President and CEO, in a statement. The deal is expected to close in March 2026, subject to customary conditions.

Chest X-rays are the most commonly performed diagnostic imaging procedure in the world. In a typical hospital, the majority of chest X-rays come back normal -- some estimates put the figure as high as 70 percent. Each one still requires a radiologist to review it, dictate a report, and sign off. In a specialty facing a global workforce shortage, this is an enormous drain on radiologist time.

Oxipit's ChestLink works by analyzing chest X-rays and autonomously clearing the ones it identifies as normal with high confidence. Only flagged or uncertain cases are routed to a radiologist for review. The result is that radiologists can focus their expertise on the cases that actually need it -- the abnormal scans, the borderline findings, the complex diagnostic puzzles -- rather than spending hours confirming that normal scans are, indeed, normal.

The CE Class IIB certification is the critical differentiator. Most AI tools in radiology operate as decision support -- they flag potential findings for a radiologist to confirm. IIB certification means the software can function as a standalone diagnostic, making final determinations without human oversight in its approved scope. Getting this certification required extensive clinical validation and represents a regulatory bar that most competitors have not cleared.

Sectra is not a startup. The company, founded in 1978 and headquartered in Linkoping, is one of Europe's largest medical imaging IT providers. Its picture archiving and communication systems (PACS) and radiology workflow solutions are deployed in thousands of hospitals globally. Annual revenue exceeds SEK 3 billion, and the company has a market capitalization north of SEK 70 billion.

For Sectra, the acquisition solves a strategic problem. The company's PACS platform is deeply embedded in hospital IT infrastructure, but it has lacked a proprietary AI layer. Competitors like Siemens Healthineers and Philips have been integrating AI directly into their imaging platforms. By acquiring Oxipit, Sectra gains autonomous AI capabilities that are pre-certified, clinically validated, and ready to deploy through its existing enterprise customer base.

The global shortage of radiologists is not a future concern -- it is a current crisis. In the UK, the Royal College of Radiologists estimates that the NHS needs 2,000 more radiologists to meet current demand. In the US, the American College of Radiology has warned about growing backlogs. European healthcare systems face similar constraints, with aging populations driving imaging volumes higher while the supply of trained radiologists remains flat.

Autonomous AI tools like ChestLink directly address this bottleneck. If a hospital can automatically clear 30 to 50 percent of its chest X-ray volume, the remaining radiologists can handle the genuinely complex cases without the crushing volume of routine normals. It does not replace radiologists -- it changes what they spend their time doing.

The deal is also notable as a cross-Baltic acquisition. Oxipit, founded in 2017 in Vilnius, Lithuania, is part of the growing Baltic AI ecosystem that has produced startups across healthcare, fintech, and cybersecurity. Lithuania's strong computer science talent pipeline, combined with access to European clinical data for training and validation, gave Oxipit the foundation to build and certify an autonomous diagnostic system.

For the Baltic tech ecosystem, the acquisition validates the strategy of building deep-tech companies with clear regulatory moats. Oxipit did not compete on features or user interface design. It competed on regulatory certification -- arguably the hardest thing to replicate in medical AI. That moat is what made it attractive to a company with Sectra's scale and distribution.

The immediate use case is chest X-ray clearance, but the technology's trajectory extends further. If autonomous AI can reliably handle chest X-rays, the same approach can be extended to other high-volume, high-normal-rate imaging modalities -- mammography screening, bone age assessment, dental imaging. Each extension requires its own clinical validation and regulatory certification, but Oxipit's ChestLink provides the proof of concept and the regulatory pathway.

For Sectra, the roadmap is clear: embed Oxipit's autonomous AI into its PACS platform, deploy it to its global hospital customer base, and expand the autonomous scope to additional imaging types over time. For the hospitals adopting it, the promise is equally clear: your radiologists do what only radiologists can do, and the AI handles the rest. In a world where imaging volumes are rising and radiologist supply is not, that proposition may prove irresistible.